E-THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.13 USD | -7.14% |
|
-.--% | -.--% |
Valuation
| Fiscal Period: January | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 71.68 | 172.2 | 119.5 | 95.46 |
| Enterprise Value (EV) 1 | 58.68 | 146.2 | 88.14 | 75.5 |
| P/E ratio | -17.3 x | -20.3 x | -13.3 x | -8.55 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 226 x | 361 x | 252 x | 300 x |
| EV / Revenue | 185 x | 307 x | 186 x | 237 x |
| EV / EBITDA | -14.5 x | -15.4 x | -8.66 x | -5.5 x |
| EV / FCF | -25.6 x | -25 x | -14.9 x | -9.21 x |
| FCF Yield | -3.9% | -4% | -6.7% | -10.9% |
| Price to Book | 5.16 x | 6.16 x | 3.62 x | 4.34 x |
| Nbr of stocks (in thousands) | 420,774 | 514,571 | 582,159 | 584,335 |
| Reference price 2 | 0.1704 | 0.3347 | 0.2053 | 0.1634 |
| Announcement Date | 5/21/21 | 5/4/22 | 5/4/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.044 | 0.456 | 0.317 | 0.477 | 0.475 | 0.318 |
| EBITDA 1 | -5.06 | -2.84 | -4.049 | -9.525 | -10.17 | -13.72 |
| EBIT 1 | -5.114 | -2.888 | -4.085 | -9.57 | -10.24 | -13.79 |
| Operating Margin | -11,622.73% | -633.33% | -1,288.64% | -2,006.29% | -2,155.58% | -4,337.74% |
| Earnings before Tax (EBT) 1 | -5.085 | -2.873 | -4.468 | -9.519 | -9.772 | -13.08 |
| Net income 1 | -3.999 | -2.347 | -3.684 | -8.07 | -8.274 | -11.17 |
| Net margin | -9,088.64% | -514.69% | -1,162.15% | -1,691.82% | -1,741.89% | -3,511.32% |
| EPS 2 | -0.0149 | -0.008729 | -0.009870 | -0.0165 | -0.0154 | -0.0191 |
| Free Cash Flow 1 | -2.92 | -1.481 | -2.29 | -5.85 | -5.904 | -8.2 |
| FCF margin | -6,636.93% | -324.78% | -722.44% | -1,226.52% | -1,242.89% | -2,578.66% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/6/19 | 3/31/20 | 5/21/21 | 5/4/22 | 5/4/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 5.9 | 3.77 | 13 | 26 | 31.4 | 20 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.92 | -1.48 | -2.29 | -5.85 | -5.9 | -8.2 |
| ROE (net income / shareholders' equity) | -45.6% | -41.5% | -40.1% | -38.6% | -27.2% | -40.6% |
| ROA (Net income/ Total Assets) | -33.2% | -29.4% | -26.7% | -27.1% | -19.9% | -28.9% |
| Assets 1 | 12.06 | 7.993 | 13.78 | 29.73 | 41.47 | 38.6 |
| Book Value Per Share 2 | 0.0300 | 0.0200 | 0.0300 | 0.0500 | 0.0600 | 0.0400 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0300 | 0.0200 | 0.0500 | 0.0400 |
| Capex 1 | 0.01 | 0.01 | 0.05 | 0.11 | 0.07 | 0.25 |
| Capex / Sales | 18.18% | 1.1% | 16.72% | 22.22% | 14.32% | 77.67% |
| Announcement Date | 3/6/19 | 3/31/20 | 5/21/21 | 5/4/22 | 5/4/23 | 6/6/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 75.96M | |
| +34.01% | 51.07B | |
| +33.84% | 38.86B | |
| -8.02% | 38.78B | |
| -8.98% | 26.69B | |
| +12.56% | 26.35B | |
| -19.62% | 19.46B | |
| +39.18% | 13.58B | |
| +31.47% | 12.46B | |
| -3.40% | 11.75B |
- Stock Market
- Equities
- ETXP.F Stock
- Financials e-therapeutics plc
